289 related articles for article (PubMed ID: 30468137)
1. Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples.
Fabbri C; Kasper S; Kautzky A; Bartova L; Dold M; Zohar J; Souery D; Montgomery S; Albani D; Raimondi I; Dikeos D; Rujescu D; Uher R; Lewis CM; Mendlewicz J; Serretti A
Br J Psychiatry; 2019 Jan; 214(1):36-41. PubMed ID: 30468137
[TBL] [Abstract][Full Text] [Related]
2. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition.
Hidalgo-Mazzei D; Berk M; Cipriani A; Cleare AJ; Florio AD; Dietch D; Geddes JR; Goodwin GM; Grunze H; Hayes JF; Jones I; Kasper S; Macritchie K; McAllister-Williams RH; Morriss R; Nayrouz S; Pappa S; Soares JC; Smith DJ; Suppes T; Talbot P; Vieta E; Watson S; Yatham LN; Young AH; Stokes PRA
Br J Psychiatry; 2019 Jan; 214(1):27-35. PubMed ID: 30520709
[TBL] [Abstract][Full Text] [Related]
3. Ketamine: stimulating antidepressant treatment?
Malhi GS; Byrow Y; Cassidy F; Cipriani A; Demyttenaere K; Frye MA; Gitlin M; Kennedy SH; Ketter TA; Lam RW; McShane R; Mitchell AJ; Ostacher MJ; Rizvi SJ; Thase ME; Tohen M
BJPsych Open; 2016 May; 2(3):e5-e9. PubMed ID: 27703782
[TBL] [Abstract][Full Text] [Related]
4. Early weight gain predicts later weight gain in depressed patients treated with antidepressants: Findings from the METADAP cohort.
Asmar KE; Fève B; Colle R; Gressier F; Vievard A; Trabado S; Verstuyft C; Haffen E; Polosan M; Ferreri F; Falissard B; Chanson P; Becquemont L; Corruble E
J Affect Disord; 2018 Dec; 241():22-28. PubMed ID: 30092445
[TBL] [Abstract][Full Text] [Related]
5. Associations between childhood maltreatment and inflammatory markers.
Palmos AB; Watson S; Hughes T; Finkelmeyer A; McAllister-Williams RH; Ferrier N; Anderson IM; Nair R; Young AH; Strawbridge R; Cleare AJ; Chung R; Frissa S; Goodwin L; Hotopf M; Hatch SL; Wang H; Collier DA; Thuret S; Breen G; Powell TR
BJPsych Open; 2019 Jan; 5(1):e3. PubMed ID: 30762500
[TBL] [Abstract][Full Text] [Related]
6. Multiple-therapy-resistant major depressive disorder: a clinically important concept.
McAllister-Williams RH; Christmas DMB; Cleare AJ; Currie A; Gledhill J; Insole L; Malizia AL; McGeever M; Morriss R; Robinson LJ; Scott M; Stokes PRA; Talbot PS; Young AH
Br J Psychiatry; 2018 May; 212(5):274-278. PubMed ID: 30517072
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
Smith MR; Sandhu S; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Stàhl O; Olmos D; Danila DC; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Lopez-Gitlitz A; Francis P; Bevans KB; Fizazi K
J Manag Care Spec Pharm; 2023 Jul; 29(7):758-768. PubMed ID: 37404070
[No Abstract] [Full Text] [Related]
8. High heterogeneity and low reliability in the diagnosis of major depression will impair the development of new drugs.
Lieblich SM; Castle DJ; Pantelis C; Hopwood M; Young AH; Everall IP
BJPsych Open; 2015 Oct; 1(2):e5-e7. PubMed ID: 27703745
[TBL] [Abstract][Full Text] [Related]
9. Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial.
Holt RIG; Gossage-Worrall R; Hind D; Bradburn MJ; McCrone P; Morris T; Edwardson C; Barnard K; Carey ME; Davies MJ; Dickens CM; Doherty Y; Etherington A; French P; Gaughran F; Greenwood KE; Kalidindi S; Khunti K; Laugharne R; Pendlebury J; Rathod S; Saxon D; Shiers D; Siddiqi N; Swaby EA; Waller G; Wright S
Br J Psychiatry; 2019 Feb; 214(2):63-73. PubMed ID: 30251622
[TBL] [Abstract][Full Text] [Related]
10. LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
J Urol; 2023 Jul; 210(1):224-226. PubMed ID: 37119051
[TBL] [Abstract][Full Text] [Related]
11. Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis.
Strawbridge R; Carter B; Marwood L; Bandelow B; Tsapekos D; Nikolova VL; Taylor R; Mantingh T; de Angel V; Patrick F; Cleare AJ; Young AH
Br J Psychiatry; 2019 Jan; 214(1):42-51. PubMed ID: 30457075
[TBL] [Abstract][Full Text] [Related]
12. CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances.
Newsome SD; Aliotta PJ; Bainbridge J; Bennett SE; Cutter G; Fenton K; Lublin F; Northrop D; Rintell D; Walker BD; Weigel M; Zackowski K; Jones DE
Int J MS Care; 2016; 18(6):314-323. PubMed ID: 27999526
[TBL] [Abstract][Full Text] [Related]
13. Annual costs among patients with major depressive disorder and the impact of key clinical events.
Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
[No Abstract] [Full Text] [Related]
14. Adjunctive simvastatin for treatment-resistant depression: study protocol of a 12-week randomised controlled trial.
Husain MI; Chaudhry IB; Khoso AB; Husain MO; Rahman RR; Hamirani MM; Hodsoll J; Carvalho AF; Husain N; Young AH
BJPsych Open; 2019 Jan; 5(1):e13. PubMed ID: 30762508
[TBL] [Abstract][Full Text] [Related]
15. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
[No Abstract] [Full Text] [Related]
16. Structural changes in amygdala nuclei, hippocampal subfields and cortical thickness following electroconvulsive therapy in treatment-resistant depression: longitudinal analysis.
Gryglewski G; Baldinger-Melich P; Seiger R; Godbersen GM; Michenthaler P; Klöbl M; Spurny B; Kautzky A; Vanicek T; Kasper S; Frey R; Lanzenberger R
Br J Psychiatry; 2019 Mar; 214(3):159-167. PubMed ID: 30442205
[TBL] [Abstract][Full Text] [Related]
17. Cognitive deficits in problematic internet use: meta-analysis of 40 studies.
Ioannidis K; Hook R; Goudriaan AE; Vlies S; Fineberg NA; Grant JE; Chamberlain SR
Br J Psychiatry; 2019 Nov; 215(5):639-646. PubMed ID: 30784392
[TBL] [Abstract][Full Text] [Related]
18. A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model.
McCormick D; Bhatt DL; Bays HE; Taub PR; Caldwell KA; Guerin CK; Steinhoff J; Ahmad Z; Singh R; Moreo K; Carter J; Heggen CL; Sapir T
J Manag Care Spec Pharm; 2020 Dec; 26(12):1517-1528. PubMed ID: 33251993
[No Abstract] [Full Text] [Related]
19. The Value of a Patient-Level Modeling Approach and Need for Better Reporting in Economic Evaluations of Osteoporosis.
Hiligsmann M; Reginster JY; Silverman S
J Manag Care Spec Pharm; 2020 Mar; 26(3):334-335. PubMed ID: 32105170
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
Blauvelt A; Shi N; Zhu B; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Murage MJ
J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
